Display options
Cite
Landeiro JA, Fonseca EO, Monnerat AL, et al. Nonfunctioning giant pituitary adenomas: Invasiveness and recurrence. Surg Neurol Int. 2015;6:179doi: 10.4103/2152-7806.170536.
Landeiro, J. A., Fonseca, E. O., Monnerat, A. L., Taboada, G. F., Cabral, G. A., & Antunes, F. (2015). Nonfunctioning giant pituitary adenomas: Invasiveness and recurrence. Surgical neurology international, 6179. https://doi.org/10.4103/2152-7806.170536
Landeiro, José Alberto, et al. "Nonfunctioning giant pituitary adenomas: Invasiveness and recurrence." Surgical neurology international vol. 6 (2015): 179. doi: https://doi.org/10.4103/2152-7806.170536
Landeiro JA, Fonseca EO, Monnerat AL, Taboada GF, Cabral GA, Antunes F. Nonfunctioning giant pituitary adenomas: Invasiveness and recurrence. Surg Neurol Int. 2015 Nov 26;6:179. doi: 10.4103/2152-7806.170536. eCollection 2015. PMID: 26674325; PMCID: PMC4665135.
Copy Download .nbib Format: NLM
Share it on

Surg Neurol Int. 2015 Nov 26;6:179. doi: 10.4103/2152-7806.170536. eCollection 2015.

Nonfunctioning giant pituitary adenomas: Invasiveness and recurrence.

Surgical neurology international

José Alberto Landeiro, Elissa Oliveira Fonseca, Andrea Lima Cruz Monnerat, Giselle Fernandes Taboada, Gustavo Augusto Porto Sereno Cabral, Felippe Antunes

Affiliations

  1. Department of Neurosurgery, Hospital Universitário Antônio Pedro, Rio de Janeiro, Brazil.
  2. Department of Pathology, Hospital Universitário Antônio Pedro, Rio de Janeiro, Brazil.
  3. Department of Endrocrinology, Hospital Universitário Antônio Pedro, Rio de Janeiro, Brazil.
  4. Department of Neurosurgery, Galeão Air Force Hospital, Rio de Janeiro, Brazil.

PMID: 26674325 PMCID: PMC4665135 DOI: 10.4103/2152-7806.170536

Abstract

BACKGROUND: We report our surgical series of 35 patients with giant nonfunctioning pituitary adenomas (GNFPA). We analyzed the rule of Ki-67 antigen expression in predicting recurrence.

METHODS: Thirty-five patients were operated between 2000 and 2010. Suprassellar extension of the tumors were classified according to Hardy and Mohr based on magnetic resonance (MR) studies. Pituitary endocrine function and MR scans were assessed preoperatively and at 1, 6, and 12 months postoperatively. Immunohistochemical studies were based in regard to the expression of the proliferative Ki-67 index and the hormonal receptor for luteinizing hormone, follicle stimulating hormone, growth hormone, thyroid stimulating hormone, adrenocorticotropic hormone, and prolactin. Tumors specimens were obtained from 35 patients with GNFPA. Endoscopic transsphenoidal surgery was the approach of choice.

RESULTS: Thirty-five patients were submitted to 49 surgeries, 44 (89.8%) were transsphenoidal and 5 (10.2%) were transcranial. The most frequent preoperative complaints were visual acuity impairment and visual field defect in 25 (71.2%) and 23 (65.7%) cases, respectively. Improvement of visual acuitiy and visual field deficit after surgery was seen in 20 (80%) and 17 (73.9%) patients, respectively. Endocrinological deficits were encountered in 20 patients (57.1%). After surgery, 18 patients (51.4%) required hormonal replacement. Three patients had visual symptoms related to pituitary apoplexy and recovered after surgery. The Ki-67 labeling index (LI) ranged from <1% to 4.8%. The rate of recurrence in tumors with Ki-67 <3% was 7.7% (2 patients), Ki-67 >3% was present in 5 patients and the recurrence committed 3 patients.

CONCLUSION: In our series, regardless the improvement of visual function and compressing symptoms, 5 patients with expression of Ki-67 LI more than 3% experienced a recurrence.

Keywords: Invasiveness; Ki-67; pituitary adenoma; recurrence

References

  1. Neurosurgery. 2007 Sep;61(3):580-4; discussion 584-5 - PubMed
  2. Surg Neurol Int. 2012;3(Suppl 2):S79-89 - PubMed
  3. Neurosurgery. 2010 Dec;67(6):1790-8; discussion 1798 - PubMed
  4. Neurosurgery. 2009 Sep;65(3):429-37; discussion 437 - PubMed
  5. Arq Bras Endocrinol Metabol. 2009 Feb;53(1):31-9 - PubMed
  6. Neurosurgery. 2000 Dec;47(6):1313-8; discussion 1318-9 - PubMed
  7. J Clin Endocrinol Metab. 2009 Nov;94(11):4406-13 - PubMed
  8. J Korean Med Sci. 2005 Jun;20(3):489-94 - PubMed
  9. J Neurooncol. 2009 May;92(3):345-56 - PubMed
  10. Asian J Neurosurg. 2010 Jan;5(1):48-53 - PubMed
  11. Clin Neurol Neurosurg. 2007 Oct;109(8):645-50 - PubMed
  12. Arq Neuropsiquiatr. 2000 Dec;58(4):1055-63 - PubMed
  13. Pituitary. 2009;12 (3):256-60 - PubMed
  14. J Neurosurg. 2002 Dec;97(5 Suppl):408-14 - PubMed
  15. J Clin Neurosci. 2008 Mar;15(3):241-5 - PubMed
  16. J Neurosurg. 2008 Apr;108(4):736-45 - PubMed
  17. Pituitary. 2009;12 (3):261-4 - PubMed
  18. Neurosurgery. 1996 Jan;38(1):99-106; discussion 106-7 - PubMed
  19. Braz J Med Biol Res. 2004 Feb;37(2):235-43 - PubMed
  20. Acta Neurochir (Wien). 2004 Aug;146(8):831-9 - PubMed
  21. Pituitary. 2013 Sep;16(3):370-7 - PubMed
  22. Eur J Endocrinol. 2006 Dec;155(6):823-9 - PubMed
  23. Endocr Pract. 2013 May-Jun;19(3):e69-73 - PubMed
  24. Surg Neurol Int. 2012;3(Suppl 2):S73-8 - PubMed
  25. Acta Neurochir Suppl (Wien). 1991;53:60-4 - PubMed
  26. Eur J Endocrinol. 2007 Aug;157(2):141-7 - PubMed
  27. Pituitary. 2012 Dec;15(4):556-61 - PubMed
  28. Eur J Endocrinol. 2007 Feb;156(2):217-24 - PubMed
  29. Neurosurgery. 2009 Apr;64(4):E773-4; discussion E774 - PubMed
  30. Can J Neurol Sci. 1990 Feb;17 (1):62-6 - PubMed
  31. J Neurosurg. 2008 Mar;108(3):525-32 - PubMed
  32. J Neurosurg. 2003 Oct;99(4):674-9 - PubMed
  33. J Clin Pathol. 1999 Feb;52(2):107-11 - PubMed
  34. Pituitary. 2013 Mar;16(1):91-100 - PubMed
  35. J Neurosurg. 2006 Dec;105 Suppl:26-30 - PubMed
  36. Neurosurgery. 1993 Oct;33(4):610-7; discussion 617-8 - PubMed
  37. Hum Pathol. 2008 May;39(5):758-66 - PubMed

Publication Types